Nectar Lifesciences Faces Revenue Reality—DRI Search Prompts Clarifications

In a development that has stirred attention across India’s pharmaceutical and compliance sectors, Nectar Lifesciences Ltd. (NECT.NS) confirmed that it has responded to clarifications and details sought by the Directorate of Revenue Intelligence (DRI) following search operations conducted at its premises. The company, which specializes in active pharmaceutical ingredients (APIs), finished dosage formulations, and contract manufacturing, is now under scrutiny for alleged irregularities related to customs and revenue disclosures.

 

The DRI, India’s apex anti-smuggling and revenue intelligence agency, carried out search operations at Nectar’s offices earlier this month, reportedly as part of a broader investigation into misclassification of imports, undervaluation, and duty evasion. While the exact nature of the probe remains confidential, sources suggest that the searches were part of a multi-agency effort to tighten compliance across the pharmaceutical supply chain.

 

Company’s Response and Regulatory Engagement

In a regulatory filing to the National Stock Exchange (NSE), Nectar Lifesciences stated that it has fully cooperated with authorities and provided all requested documentation and clarifications. The company emphasized that it is committed to maintaining transparency and regulatory compliance, and that it will continue to engage with the DRI to resolve any outstanding queries.

 

“Nectar Lifesciences has responded to all clarifications and details sought by the authority and remains committed to full cooperation,” the company said in its statement. It also reassured stakeholders that business operations remain unaffected, and that the matter is being handled with the utmost seriousness by its legal and compliance teams.

 

Market Reaction and Investor Sentiment

Following the announcement, shares of Nectar Lifesciences saw mild volatility, dipping by 1.2% intraday before recovering slightly to close flat. Trading volumes spiked, indicating heightened investor interest and concern. Analysts noted that while the DRI probe may not immediately impact earnings, reputational risks and potential penalties could weigh on the company’s medium-term outlook.

 

Nectar Lifesciences has a market capitalization of approximately ₹1,200 crore, and its stock has traded in a 52-week range of ₹13.05 to ₹56.50, reflecting both growth optimism and regulatory headwinds. The company’s recent financial disclosures have been under scrutiny, with rating agencies placing its bank facilities on Rating Watch with Negative Implications, citing delays in financial reporting and governance concerns.

 

Background: DRI’s Role and Pharma Sector Oversight

The Directorate of Revenue Intelligence plays a critical role in enforcing India’s customs laws and investigating economic offenses. In recent years, the agency has intensified its focus on the pharmaceutical sector, which is prone to complex import-export transactions, transfer pricing issues, and regulatory loopholes.

 

DRI investigations typically involve:

While Nectar Lifesciences is not the first pharma company to face such scrutiny, the case underscores the growing emphasis on compliance and transparency in a sector that contributes over $50 billion annually to India’s exports.

 

What’s Next for Nectar Lifesciences?

Industry observers expect the company to issue further updates as the investigation progresses. Legal experts suggest that if any discrepancies are found, the company could face monetary penalties, corrective action orders, or even temporary import restrictions. However, proactive cooperation and documentation could help mitigate the impact.

 

In the meantime, Nectar Lifesciences is likely to focus on:

Sources: CARE Ratings, Moneycontrol, Economic Times